Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis
Related Posts
Gunsalus RP, Humm E, Cook L, Wofford NQ, James KL, Pellegrini M, Morselli M, Ha SM, McInerney MJ. Whole genome sequence of the syntrophic benzoate-degrading[...]
Ahmad E, Ahmad S, Naeem A, Ahmed S, Shehzad M, Akram U, Ashraf H, Rehman OU, Ullah I, Ahmed R, Alraies C, Fonarow GC. Trends[...]
Asada H, Takami M, Mori S, Izawa Y, Kawamori H, Fukuzawa K. Right Coronary Artery Occlusion due to Adventitial Hematoma During Cavotricuspid Isthmus Ablation. JACC[...]